WO2006123792A1 - トリ-、テトラ-置換-3-アミノピロリジン誘導体 - Google Patents
トリ-、テトラ-置換-3-アミノピロリジン誘導体 Download PDFInfo
- Publication number
- WO2006123792A1 WO2006123792A1 PCT/JP2006/310069 JP2006310069W WO2006123792A1 WO 2006123792 A1 WO2006123792 A1 WO 2006123792A1 JP 2006310069 W JP2006310069 W JP 2006310069W WO 2006123792 A1 WO2006123792 A1 WO 2006123792A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- methyl
- amino
- dihydro
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a quinoline compound useful as a pharmaceutical, veterinary drug, marine product drug, or antibacterial preservative.
- quinolone synthetic antibacterial agents include, for example, induction of convulsions in combination with non-steroidal anti-inflammatory drugs, central effects (mild central nervous system disorders such as lightheadedness, headache, insomnia, and lethality) Serious side effects such as sexual convulsions), phototoxicity (photosensitivity), hepatotoxicity, cardiotoxicity (abnormalities observed as ECG abnormalities that cause fatal arrhythmias), delayed allergy, and blood sugar Abnormal values and the like have been clarified (see Non-Patent Documents 1 to 3).
- Patent Document 1 Japanese Patent Laid-Open No. 61-282382
- Patent Document 2 JP-A 63-45261
- Patent Document 3 JP-A-2-231475
- Patent Document 4 Japanese Patent Laid-Open No. 3-95176
- Non-patent document 1 edited by Hiroyuki Kobayashi, clinical application of new quinolone, Pharmaceutical Journal (20, 2001)
- Non-Patent Document 2 Drags, 62nd, No. 1, p. 13 (2002)
- Non-Patent Document 3 Toxicology Letters, 127, 269 (2002) Disclosure of the invention
- the present invention is a quinolone synthetic antibacterial agent and a therapeutic agent for infectious diseases, which have a broad and strong antibacterial activity against gram positive bacteria and gram negative bacteria, and have a high safety.
- the purpose is to provide.
- the inventor has conducted research focusing on a compound having a 3-aminopyrrolidinyl group at the 7-position or the equivalent position of a quinolone compound.
- the carbon atom at the 3-position has a substituent represented by an aliphatic substituent
- the carbon atom at the 4-position also represents a representative aliphatic substituent.
- the following formula has 1 or 2 substituents:
- the present invention provides a compound represented by the following formula (I), a salt thereof, or a hydrate thereof.
- R 1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms, or a substituted carbon derived from an amino acid, a dipeptide, or a tripeptide.
- an alkyl group a group selected from the group consisting of a hydroxyl group, an amino group, a halogen atom, an alkylthio group having 1 to 6 carbon atoms, and an alkoxy group having 1 to 6 carbon atoms.
- substituent group As a substituent group;
- R 2 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms.
- an alkyl group a hydroxyl group, an amino group, a halogen atom, and a carbon number 1 A substituent having a group selected from the group consisting of an alkylthio group of 1 to 6 and an alkoxy group of 1 to 6 carbon atoms;
- R 3 is a force indicating an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, or an alkyl group having 2 to 6 carbon atoms.
- a group selected from the group consisting of a hydroxyl group, an amino group, a halogen atom, an alkylthio group having 1 to 6 carbon atoms, and an alkoxy group having 1 to 6 carbon atoms has a group selected as a substituent. Be good;
- R 4 and R 5 are each independently a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, an alkyl group having 2 to 6 carbon atoms, or a carbon number of 2 To an alkynyl group having 6 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms, which includes an alkyl group, an alkoxy group, an alkyl group, and an alkyl group.
- R 4 and R 5 are not simultaneously hydrogen atoms
- a spiro ring formed in this manner may be formed by including a carbon atom to which they are bonded and forming a three-membered to six-membered ring structure to form a spirocyclic structure with a pyridine lysine ring.
- the ring may contain an oxygen atom or a sulfur atom as a constituent atom of the ring, and the ring is further substituted with an optionally substituted alkyl group having 1 to 6 carbon atoms or a halogen atom.
- exomethylene group bonded to the pyrrolidine ring by a double bond may be formed.
- this exomethylene group has a hydroxyl group, an amino group, a halogen atom, an alkylthio group having 1 to 6 carbon atoms, and a carbon number of 1 From 1 to 6 alkoxy groups may have 1 or 2 groups selected;
- R 6 and R 7 each independently represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms
- R 8 represents a halogen-substituted alkyl group having 1 to 6 carbon atoms, a halogen-substituted cycloalkyl group having 3 to 6 carbon atoms, a halogen-substituted phenyl group, or a halogen-substituted heteroaryl group;
- R 9 is a hydrogen atom, a phenyl group, a acetoxymethyl group, a bivalyloxymethyl group, an ethoxycarbonyl group, a choline group, a dimethylaminoethyl group, a 5-indal group, a phthalidyl group, or an 5 alkyl group.
- X 1 represents a hydrogen atom or a halogen atom
- A is a nitrogen atom or a formula (II)
- X 2 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a cyano group, a halogen atom, a halogen-substituted methyl group, or a halogenomethoxy group.
- This X 2 and the above R 8 may be combined to form a ring structure including a part of the mother nucleus.
- the ring formed in this way is an oxygen atom, nitrogen atom, or A sulfur atom may be contained as a constituent atom of the ring, and this ring may be substituted with an optionally substituted alkyl group having 1 to 6 carbon atoms.
- the present invention also provides a medicament comprising a compound represented by the above formula (I), a salt thereof or a hydrate thereof as an active ingredient.
- the present invention also provides a method for treating a disease, characterized by administering a compound represented by the above formula (I). Furthermore, the present invention provides use of the compound represented by the above (I) for producing a medicament.
- the present invention has strong antibacterial activity against gram-positive cocci that have become less sensitive to quinolone antibacterial drugs that are not only gram-negative bacteria, and has excellent safety and pharmacokinetics.
- a quinolone synthetic antibacterial agent having excellent properties as a medicine can be provided.
- FIG. 1 is a diagram showing the MBI action of Comparative Compound 1 and the compound of Example 9 on CYP3A4.
- FIG. 2 is a graph showing the therapeutic effect of Comparative Compound 1 and the compound of Example 9 in a PRSP mouse local lung infection model.
- FIG. 3 is a diagram showing the results of X-ray structural analysis of the compound obtained in Reference Example 107.
- FIG. 4 is a graph showing the therapeutic effect of the compound of Example 9 and comparative compound 1 in a rat simple cystitis model by Escherichia coli.
- R 1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms, or a substituted carbonyl group derived from an amino acid, a dipeptide, or a tripeptide.
- R 1 is an alkyl group
- a group selected from the group consisting of a hydroxyl group, an amino group, a halogen atom, an alkylthio group having 1 to 6 carbon atoms, and an alkoxy group having 1 to 6 carbon atoms is substituted. Have it as a group.
- R 2 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms, and in the case of an alkyl group, a hydroxyl group, an amino group, a halogen atom, carbon
- An alkylthio group having 1 to 6 carbon atoms and an alkoxy group having 1 to 6 carbon atoms may have a group selected as a substituent.
- R 1 or R 2 is an alkyl group
- these may be linear or branched, but are preferably a methyl group, an ethyl group, a propyl group, or an isopropyl group.
- a methyl group or an ethyl group is preferred, and a methyl group is more preferred.
- R 1 or R 2 is an alkyl group and has a hydroxyl group or amino group as a substituent
- the alkyl group may be linear or branched having 1 to 6 carbon atoms, and these substituents are More preferred is substitution on the terminal carbon atom of the alkyl group.
- the alkyl group having a hydroxyl group those having up to 3 carbon atoms are preferred, and a hydroxymethyl group, a 2-hydroxycetyl group, a 2-hydroxypropyl group, and a 3-hydroxypropyl group are preferable.
- the alkyl group having an amino group is preferably an aminomethyl group, a 2-aminoethyl group, a 2-aminopropyl group or a 3-aminopropyl group, preferably having up to 3 carbon atoms.
- R 1 or R 2 is an alkyl group and has a halogen atom as a substituent
- the alkyl group is a straight or branched halogen atom having 1 to 6 carbon atoms.
- a fluorine atom is preferred.
- the number of fluorine atoms may be any of mono-substitution force up to perfluoro substitution.
- a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, and a 2,2,2-trifluoroethyl group can be exemplified as preferred halogen-substituted alkyl groups.
- R 1 or R 2 is an alkyl group and has an alkylthio group or an alkoxy group as a substituent
- the alkyl group may be either a linear or branched alkylthio group.
- the alkyl part of the group or alkoxy group may be linear or branched, and may be shifted! /.
- the alkyl group having an alkylthio group is preferably an alkylthiomethyl group, an alkylthioethyl group, or an alkylthiopropyl group, and more preferably an alkylthio group having 1 to 3 carbon atoms.
- More preferable examples include a methylthiomethyl group, an ethylthiomethyl group, and a methylthioethyl group.
- the alkyl group having an alkoxy group is preferably an alkoxymethyl group, an alkoxyethyl group, or an alkoxypropyl group, and more preferably an alkoxy group having 1 to 3 carbon atoms. More preferable examples include a methoxymethyl group, an ethoxymethyl group, and a methoxyethyl group.
- R 1 or R 2 is a cycloalkyl group
- a cyclopropyl group or a cyclobutyl group is preferred, and a cyclopropyl group is more preferred.
- the substituent for the cycloalkyl group may be one or more groups selected from the group consisting of an alkyl group having 1 to 6 carbon atoms, a halogen atom, an amino group, and a hydroxyl group. Specifically, a methyl group, an ethyl group, a fluorine atom, a chlorine atom, an amino group, or a hydroxyl group is preferable as a substituent.
- R 1 is a hydrogen atom, an alkyl group, a cycloalkyl group, or a substituted carboxylic group derived from an amino acid, dipeptide, or tripeptide
- R 2 Is preferably a hydrogen atom.
- R 1 is a hydrogen atom, an alkyl group, or a cycloalkyl group
- R 2 is a hydrogen atom.
- the alkyl group a methyl group or an ethyl group is preferable, and a methyl group is particularly preferable.
- cycloalkyl group a cyclopropyl group or a cyclobutyl group is preferable, and a cyclopropyl group is particularly preferable.
- R 1 and R 2, or R 1 and R 2 are both hydrogen atoms, one of R 1 and R 2 is a hydrogen atom and the other mosquito butyl group, Echiru group , A fluorethyl group, or a cyclopropyl group.
- a quinolone derivative in which R 1 is an amino acid, dipeptide, or tripeptide-derived substituted carboxylic group and R 2 is a hydrogen atom is useful as a prodrug.
- amino acids, dipeptides, and tripeptides used to obtain such prodrugs peptide bonds formed between these carboxyl groups and an amino group to which R 1 and R 2 are bonded. Is cleaved in vivo to produce a free amine compound.
- the substituted carbo group for obtaining such a prodrug include amino acids such as glycine, alanine, and aspartic acid; glycine monoglycine, glycine monoalanine, alanine monoalanine, etc.
- Dipeptides composed of glycine, alanine, or asparagine and also tripeptides composed of glycine, alanine, or asparagine, such as glycine glycine-alanine, glycine-alanine-alanine, etc. Examples thereof include substituted carbo groups.
- R 3 represents an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, an alkyl group having 2 to 6 carbon atoms, or an alkyl group having 2 to 6 carbon atoms. .
- a group selected from the group consisting of a hydroxyl group, an amino group, a halogen atom, an alkylthio group having 1 to 6 carbon atoms, or an alkoxy group having 1 to 6 carbon atoms is used as a substituent. You may have.
- R 3 is an alkyl group
- these may be linear or branched! /, But are preferably a methyl group, an ethyl group, a propyl group, or an isopropyl group. Of these, the methyl and ethyl groups are preferred, and the methyl group is more preferred! /.
- the cycloalkyl group having 3 to 6 carbon atoms is preferably a cyclopropyl group or a cyclobutyl group, more preferably a cyclopropyl group.
- alkenyl group having 2 to 6 carbon atoms that contains one double bond.
- vinyl groups, probe groups, butyr Groups are preferred.
- an alkyl group having 2 to 6 carbon atoms may contain any one triple bond, and the triple bond may be in any position.
- Peptide groups are preferred. Of these, vinyl groups and ethynyl groups are more preferred.
- R 3 is an alkyl group, a hydroxyl group, an amino group, a halogen atom, an alkylthio group having 1 to 6 carbon atoms, and an alkoxy group having 1 to 6 carbon atoms are selected. Have, as well.
- hydroxyl group or amino group When the hydroxyl group or amino group is a substituent of an alkyl group, these are more preferably substituted on the carbon atom at the terminal of the alkyl group.
- the ru group is preferred.
- the alkyl group having an amino group is preferably an aminomethyl group, a 2-aminoethyl group, a 2-aminopropyl group, or a 3-aminopropyl group.
- the alkyl group having a hydroxyl group or an amino group is preferably a methyl group or an ethyl group, more preferably a hydroxymethyl group or aminomethyl group having these on the methyl group.
- the alkyl group When having a halogen atom as a substituent of an alkyl group, the alkyl group may be a straight chain or branched chain having 1 to 6 carbon atoms, or more preferably a halogen atom on a methyl group or an ethyl group. In particular, a methyl group is preferable.
- the halogen atom is preferably a fluorine atom.
- the number of fluorine atoms may be any of up to mono-substitution force perfluoro substitution. Examples thereof include a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, and a 2,2,2-trifluoroethyl group. A monofluoromethyl group, a difluoromethyl group, and a trifluoromethyl group are preferred.
- the alkyl group is linear or branched, and the alkylthio group or alkoxy group may be either straight or branched.
- the alkyl group having an alkylthio group an alkylthiomethyl group or an alkylthioethyl group is preferable, and an alkylthio group having 1 to 2 carbon atoms is also preferable.
- Preferable examples include a methylthiomethyl group, an ethylthiomethyl group, and a methylthioethyl group.
- the alkyl group having an alkoxy group is preferably an alkoxymethyl group or an alkoxyethyl group, and the alkoxy group is preferably one having 1 or 2 carbon atoms.
- Preferable examples include methoxymethyl group, ethoxymethyl group, and methoxyethyl group. Of these, a methylthiomethyl group and a methoxymethyl group are more preferred.
- R 3 is a cycloalkyl group
- the substituent is selected from the group consisting of an alkyl group having 1 to 6 carbon atoms, a no, a rogen atom, an amino group, and a hydroxyl group power. Any group may be used. Specifically, a methyl group, an ethyl group, a fluorine atom, or a chlorine atom is preferable.
- R 3 preferably has 1 or 2 carbon atoms, preferably a methyl group, an ethyl group, a beryl group, a fluorine-substituted methyl group or an ethyl group, an amino group or a methyl group having a hydroxyl group.
- a methyl group having a group or an ethyl group, a thiomethyl group or a methoxy group is preferred. That's right.
- R 3 is particularly preferably a methyl group or an ethyl group.
- R 4 and R 5 are each independently a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, or a carbon number.
- the alkyl group having 2 to 6 or a substituent, which may have a substituent may be a cycloalkyl group having 3 to 6 carbon atoms, but in the case of an alkyl group, a hydroxyl group, amino group, halogen atom, carbon A group selected from the group consisting of an alkylthio group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms may be used as a substituent.
- R 4 and R 5 are not hydrogen atoms at the same time.
- a spiro ring formed in this manner may be formed by including a carbon atom to which they are bonded and forming a three-membered to six-membered ring structure to form a spirocyclic structure with a pyridine lysine ring.
- the ring may contain an oxygen atom or a sulfur atom as a constituent atom of the ring, and the ring is further substituted with an optionally substituted alkyl group having 1 to 6 carbon atoms or a halogen atom.
- exomethylene group bonded to the pyrrolidine ring by a double bond may be formed.
- this exomethylene group has a hydroxyl group, an amino group, a halogen atom, an alkylthio group having 1 to 6 carbon atoms, and a carbon number of 1 1 to 6 alkoxy groups may have one or two groups selected.
- R 4 or R 5 is an alkyl group, it may be linear or branched, but is preferably a methyl group, an ethyl group, a propyl group, or an isopropyl group. Then, the methyl group and the ethyl group are preferred, and the methyl group is more preferred! /.
- R 4 or R 5 is an alkyl group and has a hydroxyl group or amino group as a substituent, those substituted on the carbon atom at the terminal of the alkyl group are more preferred.
- the alkyl group having a hydroxyl group those having up to 3 carbon atoms are preferred, and a hydroxymethyl group, a 2-hydroxyschetyl group, a 2-hydroxypropyl group, and a 3-hydroxypropyl group are preferred.
- the alkyl group having an amino group is preferably an aminomethyl group, a 2-aminoethyl group, a 2-aminopropyl group, a 3-aminopropyl group or the like having up to 3 carbon atoms.
- R 4 or R 5 is an alkyl group and has a halogen atom as a substituent
- the alkyl group is preferably a fluorine atom as the halogen atom, which may be linear or branched having 1 to 6 carbon atoms. Further, the number of fluorine atoms may be any up to mono-substitution force perfluoro substitution. Preferred examples include a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, and a 2,2,2-trifluoroethyl group.
- alkylthio or alkoxy group Te is a substituent group
- an alkyl group is linear or or branched either Yogu alkylthio alkyl alkoxy group
- the part can be straight or branched, but can be misaligned.
- the alkyl group having an alkylthio group is preferably an alkylthiomethyl group, an alkylthioethyl group, or an alkylthiopropyl group, and more preferably an alkylthio group having 1 to 3 carbon atoms. More preferable examples include a methylthiomethyl group, an ethylthiomethyl group, and a methylthioethyl group.
- the alkyl group having an alkoxy group is preferably an alkoxymethyl group, an alkoxyethyl group, or an alkoxypropyl group, and the alkoxy group is preferably one having 1 to 3 carbon atoms. More preferable examples include a methoxymethyl group, an ethoxymethyl group, and a methoxyethyl group.
- R 4 or R 5 is a cycloalkyl group
- a cyclopropyl group or a cyclobutyl group is preferred, and a cyclopropyl group is more preferred.
- the same group as the substituent when R 3 is a cycloalkyl group, and a group force consisting of an alkyl group having 1 to 6 carbon atoms, a halogen atom, an amino group, and a hydroxyl group is selected. Good. Specifically, a methyl group, an ethyl group, a fluorine atom, or a chlorine atom is preferable.
- R 4 or R 5 is a halogen atom, a fluorine atom, a chlorine atom and an iodine atom can be mentioned, and a fluorine atom is preferred.
- R 4 or R 5 is an alkoxy group
- an alkoxy group having 1 to 3 carbon atoms is preferred as long as it is an alkoxy group that also leads to the alkyl group power.
- a methoxy group, ethoxy Groups are preferred.
- R 4 or R 5 is an alkyl group or an alkyl group, it has the same meaning as R 3 .
- R 4 and R 5 form a spiro cyclic structure
- R 4 and R 5 form a polymethylene chain having 2 to 5 carbon atoms, and the polymethylene Both ends of the chain are bonded to the carbon atom to which R 4 and R 5 are bonded to form a cyclic structure.
- a 3-membered ring or a 4-membered ring is preferable, and a 3-membered ring is more preferable.
- the methylene group of the polymethylene chain may be replaced with an oxygen atom or a sulfur atom to form a saturated heterocyclic ring.
- the ring formed by combining R 4 and R 5 may have a halogen atom or a substituent, or may have an alkyl group having 1 to 6 carbon atoms as a substituent.
- the halogen atom include a fluorine atom or a chlorine atom.
- the alkyl group may be linear or branched, but is preferably a methyl group, an ethyl group, a propyl group, or an isopropyl group. A methyl group or an ethyl group is preferred.
- This alkyl group may further have a substituent, and the substituent is preferably a halogen atom.
- R 4 and R 5 are combined to form an exomethylene group bonded to the pyrrolidine ring by a double bond, R 4 and R 5 are bonded to each other to form the 4-position of the pyrrolidyl group.
- a carbon-carbon double bond is formed with one carbon atom as one carbon atom.
- the structure of the pyrrolidyl substituent moiety is as follows:
- R 41 and R 51 are both hydrogen atoms, or one is a hydrogen atom and the other is a hydroxyl group, an amino group, a halogen atom, an alkylthio group having 1 to 6 carbon atoms, or A group having a carbon number of 1 to 6 alkoxy groups.
- alkyl moieties may further have substituents.
- substituents include hydroxyl groups, amino groups, halogen atoms, alkylthio groups having 1 to 6 carbon atoms, and alkoxy groups having 1 to 6 carbon atoms. Fundamental force of the group that is selected.
- the alkylthio group having 1 to 6 carbon atoms or the alkoxyl group having 1 to 6 carbon atoms is the number of carbon atoms.
- a 1 to 3 alkylthio group or an alkoxy group is more preferable, and a methylthio group, an ethylthio group, a methoxy group, or an ethoxy group is more preferable. More preferred is a methylthio group or a methoxy group.
- Exomethylene group does not have a substituent other than a hydrogen atom, and it is preferable in some cases.
- a substituent other than a hydrogen atom a hydroxyl group, an amino group, a fluorine atom, a chlorine atom, a methylthio group, and a methoxy group are preferable. .
- R 4 and R 5 are a hydrogen atom and the other is a fluorine atom, a methyl group, Echiru group, normal propyl group, an isopropyl group, Bruno Rumarubuchiru group , Cyclopropyl group, fluoromethyl group, methoxy group, vinyl group, or ethynyl group. It is also preferred that R 4 and R 5 are in the form of a spiro ring structure containing a carbon atom to which they are bonded to form a cyclopropane ring or a cyclobutane ring. Furthermore, it is also preferred that R 4 and R 5 are combined to form an exomethylene group having 2 to 5 carbon atoms.
- R 4 or R 5 is preferably a fluoroalkyl group or a force that is a fluorine atom or united to form a spiro cyclic structure or an exomethylene group.
- R 6 and R 7 each independently represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.
- the alkyl group may be linear or branched, but is preferably a methyl group, an ethyl group, a propyl group, or an isopropyl group. Among these, a methyl group and an ethyl group are preferred. More preferred is a methyl group.
- R 6 and R 7 are preferably both hydrogen atoms.
- R 8 represents a halogen-substituted alkyl group having 1 to 6 carbon atoms, a halogen-substituted cycloalkyl group having 3 to 6 carbon atoms, a halogen-substituted phenyl group, or a halogen-substituted heteroaryl group.
- R 8 is a halogen-substituted alkyl group having 1 to 6 carbon atoms
- the alkyl group moiety may be either linear or branched, specifically, a methyl group, an ethyl group, Examples thereof include a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, and a tert-butyl group, and among these, an ethyl group is preferable.
- C substituted with an alkyl group As the rogen atom, a fluorine atom and a chlorine atom are preferable, and a fluorine atom is more preferable.
- halogen-substituted alkyl group examples include a fluormethyl group, a 1-fluoroethyl group, a 2-fluoroethyl group, and the like. Of these, a 2-fluoroethyl group is preferred.
- the cyclic alkyl group is a force that can include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, etc.
- a cyclopropyl group is preferable.
- the halogen atom substituted here include a fluorine atom and a chlorine atom, and a fluorine atom is preferred.
- the number of halogen atoms to be substituted may be one. That is, a cis monofluorocyclopropyl group is preferred!
- the halogen atom of the halogen-substituted phenyl group is preferably a fluorine atom or a chlorine atom, more preferably a fluorine atom.
- the number of halogen atom substitutions is preferably 1 or 2.
- the halogen-substituted phenyl group is preferably a 2-fluorophenol group, a 4-fluorophenol group, or a 2,4-difluorophenol group.
- the heteroaryl group in the halogen-substituted heteroaryl group may be a 5-membered or 6-membered aromatic heterocyclic group containing 1 or 2 or more heteroatoms selected from a nitrogen atom, a sulfur atom and oxygen atomic energy.
- a 5-membered or 6-membered nitrogen-containing aromatic heterocyclic group containing nitrogen atom 1 or 2 is preferred.
- pyridyl group pyrimidyl group, piperidinyl group, pyrrolidinyl group, morpholinyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, pyridyl group, pyrimidinyl group, pyridazinyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group Group, virazolidinyl group, virazolyl group, piperidyl group and piperazyl group, among which pyridyl group is preferred.
- the halogen atom is preferably a fluorine atom or a chlorine atom, more preferably a fluorine atom.
- the number of halogen atom substitutions is preferably 1 or 2.
- R 8 is preferably a halogen-substituted cycloalkyl group having 3 to 6 carbon atoms. Therefore, a 2-halogenocyclopropyl group is preferred, and a 1,2-cis-2-halogenopyl pill group, particularly a (1R, 2S) 2-halogenocyclopropyl group is particularly preferred. In addition, A nofluorocyclopropyl group is preferred, and a cis monofluorocyclopropyl group is preferred. More specifically, a 1,2-cis-2-fluorocyclopropyl group, particularly a (1R, 2S) -2 fluorocyclopropyl group is preferred.
- R 9 represents a hydrogen atom, a phenyl group, a acetoxymethyl group, a bivalyloxymethyl group, an ethoxycarbonyl group, a choline group, a dimethylaminoethyl group, a 5-indanyl group, a phthalidyl group, 5 Alkyl 2 oxo 1,3 dioxol -4-ylmethyl group, 3 acetoxy-2-oxobutyl group, alkyl group having 1 to 6 carbon atoms, alkoxymethyl group having 2 to 7 carbon atoms, or alkylene group having 1 to 6 carbon atoms A phenylalkyl group composed of a phenyl group and a force.
- R 9 is preferably a hydrogen atom.
- X 1 represents a hydrogen atom or a halogen atom.
- the halogen atom is preferably a fluorine atom or a chlorine atom, more preferably a fluorine atom.
- X 1 is preferably a fluorine atom or a hydrogen atom.
- A is a nitrogen atom or a compound of the formula (II)
- X 2 represents an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a hydrogen atom, a cyano group, a halogen atom, a halogen-substituted methyl group, or a halogenomethoxy group.
- This force X 2 and the above R 8 may be combined to form a ring structure including a part of the mother nucleus.
- the ring formed in this way is an oxygen atom, nitrogen atom, Alternatively, the ring may contain a sulfur atom as a constituent atom of the ring, and the ring may be substituted with an alkyl group having 1 to 6 carbon atoms which may have a substituent.
- A is a partial structure represented by the formula ( ⁇ ) and X 2 is an alkyl group having 1 to 6 carbon atoms, it may be either a linear or branched alkyl group, a methyl group Of these, methyl, ethyl, and ethyl are preferred. A til group is preferred, and a methyl group is more preferred.
- the alkoxy group having 1 to 6 carbon atoms may be an alkoxy group derived from the alkyl group force. Among these, an alkyl group having 1 to 3 carbon atoms or an alkoxy group having 1 to 3 carbon atoms is preferable, and a methyl group or a methoxy group is particularly preferable.
- the halogen atom is preferably a fluorine atom or a chlorine atom, more preferably a fluorine atom.
- the halogen atom of the halogen-substituted methyl group is preferably a fluorine atom or a chlorine atom, more preferably a fluorine atom.
- Examples of the halogen-substituted methyl group include a fluoromethyl group, a difluoromethyl group, and a trifluoromethyl group.
- the halogen atom is preferably a fluorine atom, more preferably a fluorine atom or a chlorine atom, and examples thereof include a fluoromethoxy group, a difluoromethoxy group, and a trifluoromethoxy group.
- a ring structure may be formed including atoms and three inter-nuclear carbon atoms to which both are bonded.
- the ring formed here is preferably a 5- to 7-membered ring, and the ring may be saturated or unsaturated.
- This cyclic structure may contain an oxygen atom, a nitrogen atom, or a sulfur atom as a constituent atom of the ring, and may be further substituted with an alkyl group having 1 to 6 carbon atoms as described for X 2 .
- the cyclic structure preferably contains an oxygen atom and is further substituted with a methyl group.
- Such a partial structure has the structure of the formula: 0—CH—CH (—CH 3) — (the rightmost carbon atom is bonded to the nitrogen atom).
- X 2 is preferably methyl, ethyl, methoxy, difluro
- a fluoromethoxy group, a cyano group, and a chlorine atom are preferable, and a methyl group, a methoxy group, and a difluoromethoxy group are particularly preferable.
- A is a partial structure represented by the formula ( ⁇ ) and the substituent X 2 forms a cyclic structure
- Benzoxazine 6 This is the case of forming a strong rubonic acid skeleton. Of these, a 3- (S) methylpyridobenzoxazine skeleton is particularly preferable.
- the compound of the present invention has the following formula at the 7-position (or equivalent position) of the quinoline skeleton:
- the pyrrolidinyl group has an amino group at the 3-position of the pyrrolidinyl group, and the substituent R 3 that is not a hydrogen atom is substituted on the carbon atom substituted by the amino group, and the carbon atom at the 4-position is mono- or di-substituted.
- the 3-position of the 1-pyrrolidyl group includes a 3-amino group and is di-substituted
- the 4-position is mono- or di-substituted and is tri- or tetra-substituted at the 3- and 4-positions.
- the feature is that it is replaced.
- This pyrrolidinyl group contains an asymmetric carbon atom, and this stereogenicity will be described.
- R 4 and R 5 are not hydrogen atoms (including when they are combined together), the following structure in which the amino group is j8-coordinated:
- R 4 and R 5 are hydrogen atoms, the following four types:
- the structure having a structure of 1 is preferable to the structure of 4, but the deviation is preferred or changes depending on the structure of the substituent R 5 .
- the present invention includes! And misplaced ones.
- preferred compounds are compounds in which the previously exemplified 7-position substituent is substituted on the quinolone carboxylic acid basic skeleton exemplified above (a combination of the exemplified nucleus and substituent). It is.
- the absolute configuration at the 3-position substituted by the amino group on the pyrrolidine ring is either 3R or 3S. Further, it is preferable that the compound of the present invention is sterically single. /.
- Benzoxazine 6 strong rubonic acid, its salts, or their hydrates
- a 3-amino-3methyl-4-alkyl-substituted pyridine lysine derivative (8) which is a representative substituent compound of the present invention, comprises a 3-substituted crotonic acid ester (1) and an azomethine ylide (2) as a reactive element. It can be produced by synthesizing key synthetic intermediates using 1,3 dipole cycloaddition reactions and converting the ester moiety to amin after hydrolysis.
- the present inventor has selected a tertiary butoxycarbonyl group as a protecting group for the amine moiety at the 3-position, and the protecting group for the amino group at the 3-position is a group other than the tertiary butoxycarbonyl group.
- optically active substance may be a protecting group that does not affect each reaction step and can be easily deprotected later, and may be the same protecting group as the 1st position.
- the synthesis of the optically active substance can be performed, for example, using optical resolution with an appropriate intermediate. Specific examples thereof include appropriate intermediates. Using a chiral column for HPLC and diastereomeric salt preferential crystallization, or by coupling a chiral element to an appropriate intermediate to induce a diastereomer and then diastereomer using an appropriate separation technique such as silica gel chromatography. For example, a method in which the chiral element is removed and led to an optically active substance can be used. Furthermore, chiral building blocks can be synthesized as starting materials.
- Boc represents a tertiary butoxycarbonyl group
- Cbz represents a benzyloxycarbonyl group
- R 1C represents an alkyl group having 1 to 6 carbon atoms
- R 11 represents a substituent obtained by removing a hydrogen atom from R 4 or R 5 described in formula (I).
- Step 1 is a 1-, 3-dipolar cycloaddition reaction using a 3-substituted crotonic acid ester (1) and an azomethine ylide (2) as reaction elements.
- This is a step of synthesizing the derivative (3).
- the reagent and method for producing the reaction active element azomethine ylide is, for example, by adding a catalytic amount of trifluoroacetic acid or a catalytic amount of silver fluoride to N-benzylthio N- (methoxymethyl) trimethylsilylmethylamine. Generate [see Journal of Organic Chemistry, Vol. 52, No. 2, p. 235 (1987)].
- reaction solvent any solvent can be used as long as it does not form an azomethine ylide and does not inhibit the 1,3 dipolar cycloaddition reaction.
- Preferred are dichloromethane and 1,2-dichloroethane.
- Reaction temperature from 20 ° C to solvent reflux
- the room temperature force is also the temperature at which the solvent is refluxed.
- Step 2 is a step of converting the protecting group at the 1-position of the pyrrolidine ring. This step should be carried out in order to easily extract, isolate and purify the carboxylic acid derivative produced after hydrolysis of the 3-position ester.
- the protecting group at the 1-position is preferably distinguished from the protecting group for the 3-position amino group subsequently produced after the conversion in the deprotection step, but may be the same.
- a preferable example of the protecting group at the 1-position is a benzyloxycarbonyl group.
- This benzyloxycarbonylation reaction is usually carried out by a direct conversion method using a von Braun reaction using benzyl chloroformate in a solvent such as dichloromethane, or by contact using a catalyst such as noradium-carbon. After hydrogenolysis, it can be carried out by a method of reacting benzyl chromate formate in an appropriate solvent in the presence of a base.
- Step 3 is a hydrolysis step of an ester at the 3-position of the pyrrolidine ring.
- Esters are alkyl esters having 1 to 6 carbon atoms, preferably methyl esters, ethyl esters, and tertiary butyl esters.
- hydrolysis with a base or acid is performed as long as the conditions do not affect the protective group at the 1-position.
- Hydrolysis of methyl ester and ethyl ester does not affect the protective group at the 1-position after reaction with ethanol or water in aqueous alkali solution such as sodium hydroxide aqueous solution, potassium hydroxide aqueous solution or barium hydroxide aqueous solution. Isolate and purify with an appropriate acid.
- the tertiary butyl ester is hydrolyzed in an appropriate solvent in which the ester is dissolved under acidic conditions or in the presence of an acid catalyst.
- Preferred acids include hydrochloric acid, formic acid, acetic acid, trifluoroacetic acid, p-toluenesulfonic acid and the like.
- Step 4 is a step of converting the carboxy group at the 3-position of the pyrrolidine ring into an amino group.
- This step is usually performed using a rearrangement reaction to a carboxylic acid amine.
- a reagent such as sodium azide, trimethylsilyl azide, diphenylphosphoric acid azide (DPPA) is used, and the carboxylic acid is converted to the acid azide in an appropriate solvent such as toluene.
- the reaction solution is heated to form isocyanate and converted to amine by hydrolysis using hydrochloric acid or the like.
- step 5 the following steps can be performed without performing force protection, which is a step of protecting the amino group at the 3-position of the pyrrolidine ring.
- a protecting group for 3-position amino group it is usually used. However, it is preferable to distinguish the protecting group at the 1-position from the deprotecting step.
- a tertiary butoxycarbonyl group which is a tertiary butoxycarbonyl group, a acetyl group or a trifluoroacetyl group is preferable.
- Steps 4 and 5 can be performed in one step by performing the rearrangement reaction using an appropriate solvent.
- an appropriate solvent for example, by performing the Curtius rearrangement reaction in tertiary butyl alcohol using diphenyl phosphate azide (DPPA), a 3- (tertiary butoxycarbol) aminopyrrolidine derivative can be obtained.
- DPPA diphenyl phosphate azide
- Step 6 is a step of deprotecting the 1-position of the pyrrolidine ring, but the deprotection reaction may be performed under any conditions as long as other functional groups and configuration are not changed. Therefore, in the case of the compounds of the invention of the present application, the representative protecting group at the 1-position is a benzyloxycarbon group. Or by catalytic hydrogenolysis using ammonium formate in a protic polar solvent. In addition, when the 4-position of the pyrrolidine ring has a carbon-carbon unsaturated bond such as a bur group or a methylene group as a substituent, it must be deprotected while retaining the carbon-carbon unsaturated bond.
- the protecting group at the 1-position is a benzyloxycarboro group, it retains a carbon-carbon unsaturated bond such as a buryl group and a methylene group at the 4-position of the pyrrolidine ring.
- the deprotection conditions include, for example, a method using strong acid conditions (for example, hydrobromic acid acetic acid, trifluoroacetic acid, trifluoromethanesulfonic acid-trifluoroacetic acid), sodium liquid ammonia (perch reducing conditions), barium hydroxide And the like.
- Another representative compound of the present invention 7 amino-7-methyl-5 azaspiro [2.4] heptane derivative (17), was synthesized with the amino-tolyl derivative using the Strecker reaction of the ketone moiety of the acetate acetate derivative. After that, it can be produced by a method in which a cyano group is reduced and converted to an aminomethyl group, condensed with an ester moiety (carboxylic acid unit), and via a pyrrolidone derivative which is an important intermediate.
- the present inventor selected a tertiary butoxycarbonyl group as a protecting group for the amine moiety at the 3-position.
- the protecting group of the amino group at the 3-position is a group other than the tertiary butoxycarbonyl group, the protecting group can be easily deprotected later without causing adverse effects such as inhibiting each reaction step. It may also be the same protecting group as the 1-position.
- the synthesis of the optically active substance can be performed, for example, using optical resolution with an appropriate intermediate.
- a method of separating diastereomers using an appropriate separation technique such as removing a chiral element and leading to an optically active substance can be used.
- chiral building blocks can be synthesized as starting materials.
- Boc represents a tertiary butoxycarbonyl group
- R 12 represents an alkyl group having 1 to 6 carbon atoms.
- Step 7 is a step of constructing a cyclic structure in the methylene moiety of the acetoacetate derivative.
- 1,2-dihalogenoethane such as dibromoethane may be used as an alkylating agent in the presence of a base.
- a base potassium carbonate, sodium hydride, sodium metal, etc. are used.
- the reaction solvent acetone, N, N-dimethylformamide is used. I can make it.
- the cyclo compound can be separated and purified by distillation under reduced pressure.
- Step 8 is a step of converting a methyl ketone moiety into an amino-tolyl derivative by a Strecker reaction.
- This Strecker reaction is carried out in the presence of ammonium chloride as appropriate by the action of ammonia and a cyanide agent such as potassium cyanide.
- the reaction conditions may be appropriately selected with reference to the Strecker method often used in amino acid synthesis.
- Step 9 is a step of reducing the cyan group to convert it to methylamine.
- This reduction of -tolyl is usually carried out by catalytic reduction in an appropriate solvent such as ethanol in the presence of a catalyst.
- the catalyst include a palladium carbon catalyst, Raney nickel, Raney cobalt and acid platinum. If secondary amine is by-produced when catalytically reducing nitrile, it is better to coexist with ammonia.
- other functional groups of the substrate for example, an ester group that is a specific example of the compound of the present invention can be used, and reduction with a metal hydride compound can also be used.
- a reagent such as sodium borohydride monosalt-cobalt ( ⁇ ) may be used, but when the ester moiety is reduced, tertiary butyl ester or the like is not bulky. Convert to ester.
- Step 10 is a step of obtaining a pyrrolidone derivative by condensing an ester moiety (carboxylic acid unit) and methylamine in the molecule.
- ester partial force s methyl ester and ethyl ester
- the reaction is completed by heating the reaction solution from room temperature in an appropriate solvent.
- step 11 the next step and subsequent steps can be carried out without performing force protection, which is a step of protecting the amino group at the 3-position on the pyrrolidine ring.
- the protecting group for the 3-position amino group a commonly used protecting group for an amino group that is stable under the reaction conditions in Step 13 described later can be used. What is distinguished in a deprotection process is preferable. Specific examples are tertiary butoxycarbol groups, acetyl groups, and trifluoroacetyl groups. Force Tertiary butoxycarbol group.
- Step 12 is a step for protecting the 1-position of the pyrrolidine ring, but it is also possible to carry out the following steps and subsequent steps without protection.
- the protecting group at the 1-position a commonly used amino protecting group which is stable under the reaction conditions of Step 13 described later can be used, but preferably, the protecting group of the amino group at the 3-position and deprotection are used. What is distinguished by a process is preferable.
- the present inventor selected a benzyl group.
- the benzyl ester reaction is carried out using benzyl iodide in the presence of a base such as sodium hydride or potassium carbonate.
- the reaction solvent include acetone, N, N dimethylformamide, tetrahydrofuran, and a mixed solvent thereof.
- Step 13 is a step of reducing the pyrrolidone carboyl group.
- metal hydride compounds such as lithium aluminum hydride and sodium bis (2-methoxyethoxy) aluminum hydride
- borohydride compounds such as diborane and borane-tetrahydrofuran complex are used.
- an ether solvent typically tetrahydrofuran, as the solvent and perform the reaction at a temperature of -78 ° C to 100 ° C!
- Step 14 is a step of deprotecting the 1-position of the pyrrolidine ring, but the deprotection reaction may be carried out under any conditions as long as other functional groups and configuration are not changed. Therefore, when the compounds of the present invention are concerned, the protecting group at the 1-position is a benzyl group, so that it is usually used under deprotection conditions, for example, catalytic conditions such as noradium-carbon, or in a protic polar solvent. By catalytic hydrogenolysis using ammonium formate.
- the 4-position of the pyridolysine ring has a carbon-carbon unsaturated bond such as a vinyl group or a methylene group as a substituent, it must be deprotected while retaining the carbon-carbon unsaturated bond. Therefore, in the case of the compounds of the present invention, since the protecting group at the 1-position is a benzyl group, it is removed while retaining a carbon-carbon unsaturated bond such as a vinyl group or a methylene group at the 4-position of the pyrrolidine ring.
- the conditions for protection include a method using sodium-liquid ammonia (perch reducing conditions).
- R 8 , X 1 and A are as defined above; R 91 represents a hydrogen atom, dihalogeno boron, or diacyl boron, and X represents a leaving group.
- the compound (8) or the compound (17) can be reacted with a quinolone mother nucleus compound represented by the following formula.
- R 91 of the quinolone mother nucleus compound is a hydrogen atom or a boron substituent capable of forming a boron chelate.
- the boron substituent can include dihalogenoboron or diacyloxyboron. As dinologenoboron, difluoroboron (one BF) is preferred.
- Diacetyloxyboron [B (OAc)] is preferred as diacyloxyboron.
- the target compound can be obtained by dissolving the quinolone mother nucleus compound in a suitable solvent and reacting with the compound for introducing a 7-position substituent (8) or (17) in the presence of a base.
- the amino group of the compound for introducing the 7-position substituent may be protected as tert butyl
- oxycarbonyl (Boc) group benzyloxycarbonyl group, p-methoxybenzyloxycarbonyl group, acetyl group, methoxyacetyl group, trifluoroacetyl group, pivaloyl group, formyl group, benzoyl group, A tert-butyl group, a benzyl group, a trimethylsilyl group, an isopropyldimethylsilyl group, or the like can be used.
- Bases include alkali metal or alkaline earth metal carbonates, hydrogen carbonates or hydroxide salts, trialkylamines such as triethylamine, N, N-diisopropylethylamine, pyridine, 1, 8— Nitrogen-containing heterocyclic compounds such as diazabicycloundecene and N-methylbiperidine can be used, but trialkylamines and triethylamine are preferred.
- the solvent to be used is not particularly limited as long as it does not inhibit the reaction, and N, N-dimethylformamide, dimethyl sulfoxide, sulfolane, acetonitrile, ethanol, dimethylacetamide, tetrahydrofuran or N-methylpyrrolidone can be used. Particularly preferred is dimethyl sulfoxide or sulfolane.
- the quinolone mother nucleus compound is a boron chelate compound
- the boron substituent moiety is hydrolyzed and cleaved, and then the protecting group of the amino group is deprotected, whereby the target compound is obtained.
- the hydrolysis of the boron substituent may be performed under the conditions usually used. For example, it can be carried out by reacting a base in an alcohol solvent such as methanol or ethanol. Triethylamine is preferred as the base.
- the reaction is preferably carried out under ice cooling. Deprotection can be carried out under conditions suitable for the protecting group used, for example, by treating the hydrolyzate with concentrated hydrochloric acid.
- the reaction solution is made basic with, for example, aqueous sodium hydroxide solution.
- R 11 represents R 1 (a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms, or an amino acid, a dipeptide, Or a force indicating a substituted carbocyclic group derived from a tripeptide.
- R 1 a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms, or an amino acid, a dipeptide, Or a force indicating a substituted carbocyclic group derived from a tripeptide.
- R 1 a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms, or an amino acid, a dipeptide, Or a force indicating a substituted carbocyclic group derived from a tripeptide.
- an alkyl group a hydroxyl group, an amino group,
- R 21 represents a previously defined R 2 (a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms.
- R 2 a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms.
- R 21 represents a previously defined R 2 (a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms.
- R 2 represents a previously defined R 2 (a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cycloalkyl group having 3 to 6 carbon atoms.
- R 3 , R 4 , R 5 , R 6 and R 7 are the same as already defined. )
- alkoxy carbo yl groups such as a tertiary butoxy carbo yl group and a 2,2,2-trichloro ethoxy carbo ol group
- Aralkyloxycarbon groups such as benzyloxycarbol group, paramethoxybenzyloxycarbol group, para-trobenzyloxycarboxyl group
- acetylyl group methoxyacetyl group, trifluoroacetyl group, chloro Acyl groups such as acetyl group, pivaloyl group, formyl group, benzoyl group
- alkyl groups such as tertiary butyl group, benzyl group, para-trobenzyl group, paramethoxybenzyl group, triphenylmethyl group, or aralkyl groups
- Ethers such as methoxy carbo yl groups such as a tertiary butoxy carbo yl group and a 2,2,2-trichloro ethoxy
- the protecting group represented by R 13 is not particularly limited as long as it is widely used in this field.
- a tertiary butoxycarbonyl group, a 2,2,2-trichloroethoxy group, etc. Alkoxycarboxyl groups; aralkyloxycarbol groups such as benzyloxycarbol group, paramethoxybenzyloxycarbol group, para-trobenzyloxycarbol group; acetyl Groups, methoxyacetyl groups, trifluoroacetyl groups, chloroacetyl groups, bivaloyl groups, formyl groups, benzoyl groups, etc .; tertiary butyl groups, benzyl groups, para-trobenzyl groups, paramethoxybenzyl groups , Alkyl groups such as trifluoromethyl group, or aralkyl groups; methoxymethyl group, tertiary butoxymethyl group, tetrahydrobiral group, 2, 2, 2-trichloroeth
- Which protecting group is selected when two or more of RU, R 21 and R 13 are protecting groups can be selected in this field so that it can be selectively removed when preparing compound (19) or (20). You can choose based on your normal knowledge.
- Example 9 shows strong antibacterial activity and has excellent stability and pharmacokinetics, as will be apparent from the following test examples.
- Structural analysis revealed that the absolute configuration of the asymmetric carbon moiety at the 7-position of the 5-azaspiro [2.4] heptane-5-yl group (site substituted with an amino group) was (7S). . From this, among the quinolone compounds having a spironicyclic substituent, more preferably, The compound was confirmed to be (S) at the 7-position of the pyrobicyclic substituent.
- the compound of the present invention Since the compound of the present invention has a strong antibacterial action, it can be used as a medicine for humans, animals and fish, or as a preservative for agricultural chemicals and foods.
- the dosage is 50 mg to: Lg per adult day, more preferably 100 to 500 mg.
- the dose for animals varies depending on the purpose of administration, the size of the animal to be treated, the type and degree of pathogenic bacteria infected, but is generally 1 to 200 mg per kg of animal body weight as a daily dose. 5 ⁇ : LOOmg power is preferred! This dose is given once a day or divided into 2 to 4 times. The daily dose may exceed the above amount if necessary.
- the compounds of the present invention are active against a wide range of microorganisms that cause various infectious diseases, and can treat, prevent or alleviate diseases caused by these pathogens.
- bacteria or bacteria-like microorganisms in which the compound of the present invention is effective include Staphylococcus, Streptococcus pyogenes, Streptococcus haemolyticus, Enterococcus, Streptococcus pneumoniae, Streptococcus spp.
- Examples include Shigella genus, Klebsiella pneumoniae, Enterobacter genus, Serratia genus, Proteus genus, Pseudomonas aeruginosa, Infnorenza bacterium, Acinetopacter genus, Campylobacter genus, Trachoma chlamydia and the like.
- Diseases caused by these pathogens include folliculitis, tsutsu, yo, erysipelas, cellulitis, lymphangitis (hypodenitis), hail poultry, subcutaneous abscess, sweat gland, congestive acne, infectious powder Aneurysm, perianal abscess, mastitis, trauma ⁇ burn ⁇ superficial secondary infection such as surgical wound, sore throat, acute bronchitis, tonsillitis, chronic bronchitis, bronchiectasis, diffuse panbronchiolitis Chronic respiratory disease secondary infection, pneumonia, pyelonephritis, cystitis, prostatitis, accessory testicularitis, gonococcal urethritis, nongonococcal urethritis, cholecystitis, cholangitis, bacterial dysentery, enteritis, uterine appendage Inflammation, intrauterine infection, bartholinitis, blepharitis, st
- the Mycobacterium tuberculosis group Mycobacterium tubaclosis, M. bobius, M. africanum
- the atypical acid-fast bacterium group M. Kansasi, M. Malainam, M. Scrofaceum, M. Abium, M. Intracellulare, M. Xeno Bi, M. Forche Yutam, M. Cellonet.
- Mycobacterial infections caused by these pathogens are broadly classified into three categories: tuberculosis, atypical mycobacterial diseases, and leprosy.
- Mycobacterium tuberculosis infection includes lung, trachea, bronchi, lymph node, systemic dissemination, bone joint, meninges, brain, digestive organ (intestine, liver), skin, mammary gland, eye, middle ear • pharynx It is found in the urinary tract, male genitals, female genitals, etc.
- the main affected organ of atypical mycobacterial disease is the lung, and other local lymphadenitis, soft skin tissue, bone joint, systemic dissemination type, etc. Can do.
- infectious diseases in animals, for example, Escherichia, Salmonella, Nosullella, Hemophilus, Bordetella, Stahirococcus, Mycoplasma, etc.
- Specific diseases include colibacillosis, chicken dysentery, fowl typhoid, poultry cholera, infectious coryza, staphylococci, and mycoplasma infection in swine, colibacillosis, salmonellosis, pastrellosis, and hemophilus infection in swine. , Atrophic rhinitis, exudative dermatitis, mycoplasma infection, etc.
- the antibacterial agent containing the compound of the present invention can be prepared by selecting an appropriate preparation according to the administration method and preparing V for general use.
- Examples of the dosage form of the antibacterial agent comprising the compound of the present invention as the main ingredient include tablets, powders, granules, capsules, solutions, syrups, elixirs, oily or aqueous suspensions, and the like. it can.
- stabilizers, preservatives, solution adjuvants, etc. may be used in the preparation.
- After storing the solution that may contain these in a container prepare as a solid preparation by lyophilization etc. It may be a preparation of
- multiple doses may be stored in the same container, even if one dose is stored in the container.
- Examples of the preparation for external use include solutions, suspensions, emulsions, ointments, gels, creams, lotions, sprays and the like.
- the solid preparation may contain pharmaceutically acceptable additives together with the active compound.
- the additive include fillers, binders, disintegrants, solutions, and the like. Promotion Examples thereof include agents, wetting agents, lubricants and the like.
- liquid preparations include solutions, suspensions, and emulsions, but suspending agents, emulsifiers, and the like may be included as additives.
- Ethyl tiglate (6.41 g, 50. Ommol) and N benzyl o- (methoxymethyl) -N trimethylsilylmethylamine (15.35 g, 60. Ommol) in dichloromethane (15 OmL) at room temperature
- a catalytic amount of trifluoroacetic acid was added, and the mixture was heated and stirred for 10 hours in an oil bath at 40 ° C.
- the reaction mixture was diluted with ethyl acetate (500 mL), washed with saturated aqueous sodium hydrogen carbonate (200 mL) and saturated brine (200 mL), and dried over anhydrous sodium sulfate.
- the obtained isocyanate crude product was dissolved in 1,4 dioxane (15 mL), 6N hydrochloric acid (15 mL) was added, and the mixture was heated and stirred for 1 hour in a 50 ° C oil bath. The reaction mixture was concentrated under reduced pressure and azeotroped with ethanol (5 times). The residue was dissolved in dichloromethane (30 mL), triethylamine (3.72 mL, 26.69 mmo 1) at room temperature, and then di-tert-butyldioxide. Carbonate (2.33 g, 10.68 mmol) was added.
- the reaction solution was concentrated under reduced pressure, the residue was dissolved in ethyl acetate (150 mL), and washed with 10% aqueous citrate solution (80 mL), water (80 mL ⁇ 2) and saturated brine (80 mL).
- the organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- (+)-(3R *, 4S *)-1-benzyloxycarbo dilu-3- (tert-butoxycarbonylamino) -4 fluoromethyl-3-methylpyrrolidine (310 mg) , 0.86 mmol) to (3R *, 4S *) — 3— (tert-butoxycarbo-lumino) — 4-fluoromethyl—3-methylpyrrolidine crude product, and then 6, 7-difluoro 1— [ (1R, 2S) —2 Fluorocyclopropyl] —8-Methoxy-1,1,4 dihydric mouth —4-oxoquinoline—3-carboxylic acid 'difluoroboron complex (305 mg, 0.846 mmol) and the title compound 257 mg (0.516 mmol, 61%) was obtained as a white powder.
- the aqueous layer was extracted with jetyl ether (2 L), and water (1 L) was collected in the resulting aqueous layer, followed by further extraction with jetyl ether (2 L). After all the organic layers were combined, the organic layer was washed with a 10% aqueous citrate solution (2 L), water (2 L ⁇ 3), and saturated brine (2 L ⁇ 3), and dried over anhydrous sodium sulfate. After the desiccant was filtered off, the solvent was distilled off under reduced pressure, and the resulting residue was distilled under reduced pressure to obtain 371.8 g (10 mmHg, 72-78 ° C fraction, 2.02 mol, 67%) of the target compound as colorless. Obtained as a clear oil.
- 1-Acetyl- 1-cyclopropanecarboxylic acid tert-butyl ester (9.21 g, 50. Ommol) is dissolved in 7N ammonia Z methanol solution (300 mL), concentrated ice water (90 mL) under ice cooling, Ammonium chloride (53.5 g, 1. OOmol) and sodium cyanide (4.90 g, 100. Ommol) were added and then stirred at room temperature for 18 hours. Concentrate the solvent under reduced pressure, add water (lOOmL) to the remaining liquid, and then add dichloromethane (300mL + 2 X lOOmL). Extracted. To the combined organic layers, anhydrous sodium sulfate was added and dried.
- (+)-5 Benzyl-7- (tert-butoxycarbo-lamino) -7-methyl-5-azaspiro [2.4] heptane-4-one (950mg, 2.88mmol)
- a crude product of 7-amino-5-benzyl-1-7-methyl-5-azaspiro [2.4] heptane was obtained as a colorless transparent oil.
- (+)-5 Benzyl-7- (tert-butoxycarbo-lamino) -7-methyl-5-azaspiro [2.4] heptane (627mg, 1.981mmol) in methanol (40mL) 10% Palladium carbon catalyst (M, about 50% water content, 376 mg) was added, and the mixture was stirred at room temperature for 5 hours in a hydrogen gas atmosphere. After removing the catalyst by filtration, the solvent was distilled off under reduced pressure to obtain 452 mg (quantitative) of the target compound crude product as a colorless transparent gummy solid.
- the reaction mixture was concentrated under reduced pressure, the residue was dissolved in ethyl acetate (200 mL), and washed with 10% aqueous citrate solution (50 mL), water (50 mL ⁇ 2), and saturated brine (50 mL). After drying the organic layer over anhydrous sodium sulfate, the solvent is distilled off under reduced pressure. Thus, 870 mg (l. 676 mmol, 91%) of a crude target compound was obtained as a yellow foamy solid.
- isopropyl alcohol 180 mL was added and stirred for a while on a 50 ° C. water bath to crystallize the gummy insoluble matter. After standing at room temperature for 1 hour, the crystals were collected by filtration, and the obtained crystals were washed with a small amount of isopropyl alcohol (twice). Drying under reduced pressure gave 12.91 g (27.2 mmol, 69%) of the title compound as a yellow powder.
- the reaction mixture was poured into ice-cooled 0.5N hydrochloric acid (1 L) and extracted with ethyl acetate (2 L + 1 L). The organic layers were combined, washed with water (1 LX 2) and saturated brine (1 L), dried over anhydrous sodium sulfate, the desiccant was filtered off, and the solvent was distilled off under reduced pressure.
- the resulting crude product was purified by silica gel column chromatography (hexane acetate: 80:20 ⁇ 67:33 ⁇ 50:50 ⁇ 33:67) to give stereoisomer A with respect to position 3 of the title compound.
- the reaction solution was concentrated under reduced pressure, and the residue was acidified with concentrated hydrochloric acid under ice-cooling, followed by extraction with black mouth form (300 mL + 2 ⁇ 10 mL).
- the organic layers were combined and dried over anhydrous sodium sulfate.
- the desiccant was removed by filtration, and the solvent was distilled off under reduced pressure to obtain 11.46 g (quantitative) of the title compound crude product as a light brown solid.
- the obtained crude product was used in the next reaction without further purification.
- reaction solution was concentrated under reduced pressure, azeotroped with ethanol, water (lOOmL) was added to the residue, and the mixture was made alkaline with a saturated aqueous sodium hydroxide solution while stirring with ice cooling.
- the mixture was extracted with dichloromethane (6 OOmL + lOOmL), and the organic layers were combined and dried over anhydrous sodium sulfate.
- stereoisomer AA 1. 41 g ((3R *, 4R *) Body, 5.72 mmol, 2 steps, 16%) was obtained as a light brown gummy solid.
- the reaction mixture is ice-cooled, water (1.22 mL, 67.7 mmol), 15% aqueous sodium hydroxide solution (1.22 mL), and Water (3.66 mL) was carefully added sequentially, and the mixture was stirred at room temperature overnight. Insoluble matter was removed by filtration, and the residue was washed with tetrahydrofuran (3 times), and the filtrate and washing solution were combined and the solvent was distilled off under reduced pressure. The obtained residue was dissolved in dichloromethane (70 mL), ditert-butyl dicarbonate (5.53 g, 25.3 mmol) was added, and the mixture was stirred at room temperature for 25 hours.
- the reaction mixture was diluted with ethyl acetate (200 mL) and washed successively with saturated aqueous sodium hydrogen carbonate (50 mL), water (50 mL), and saturated brine (50 mL).
- the obtained organic layer was dried over anhydrous sodium sulfate, the desiccant was filtered off, and the solvent was distilled off under reduced pressure to obtain a crude isocyanate product.
- the obtained crude isocyanate product was dissolved in 1,4 dioxane (16 mL), 6N hydrochloric acid (16 mL) was added, and the mixture was heated and stirred in an oil bath at 60 ° C. for 3.5 hours.
- the reaction solution was concentrated under reduced pressure, azeotroped with ethanol, water (30 mL) was added to the residue, and the mixture was made alkaline by adding a saturated aqueous sodium hydroxide solution with stirring under ice cooling.
- the resulting mixture was extracted with dichloromethane (150 mL + 2 ⁇ 50 mL), the organic layers were combined and dried over anhydrous sodium sulfate, the desiccant was filtered off, and the solvent was distilled off under reduced pressure.
- the crude target compound 1.79 g (quantitative) was obtained as a greenish brown oil. The obtained crude product was used in the next reaction without further purification.
- reaction solution was poured into a cold aqueous citrate solution (1 L of 10% citrate and 500 g of ice), stirred for 30 minutes, and extracted with ethyl acetate (800 mL, 500 mL). The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
- IR (ATR) v 3363, 2978, 2935, 2360, 1716, 1684, 1489, 1456, 1369, 1 304, 1269, 1230, 1167cm '' 1 .
- IR (ATR) v 3450, 2976, 2931, 2785, 2359, 1790, 1720, 1603, 1493, 1
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ562959A NZ562959A (en) | 2005-05-19 | 2006-05-19 | Tri- or tetra-substituted-3-aminopyrrolidine derivatives |
JP2007516357A JP5087394B2 (ja) | 2005-05-19 | 2006-05-19 | トリ−、テトラ−置換−3−アミノピロリジン誘導体 |
CA2608468A CA2608468C (en) | 2005-05-19 | 2006-05-19 | Tri-, tetra-substituted-3-aminopyrrolidine derivative |
EP06746676.3A EP1882689B1 (en) | 2005-05-19 | 2006-05-19 | Tri- or tetra-substituted-3-aminopyrrolidine derivatives |
CN2006800172069A CN101189222B (zh) | 2005-05-19 | 2006-05-19 | 三-、四-取代-3-氨基吡咯烷衍生物 |
ES06746676T ES2422858T3 (es) | 2005-05-19 | 2006-05-19 | Derivados de 3-aminopirrolidina tri- o tetra-sustituidos |
KR1020077026606A KR101307717B1 (ko) | 2005-05-19 | 2006-05-19 | 트리―, 테트라― 치환―3―아미노피롤리딘 유도체 |
AU2006248354A AU2006248354B2 (en) | 2005-05-19 | 2006-05-19 | Tri- or tetra-substituted-3-aminopyrrolidine derivatives |
BRPI0610114-3A BRPI0610114A2 (pt) | 2005-05-19 | 2006-05-19 | derivados de 3-aminopirrolidina tri- ou tetra-substituìdos |
IL186815A IL186815A (en) | 2005-05-19 | 2007-10-21 | A 3-amino-3-alkyl-4-quinolone compound mono or 3-amino-3-alkyl-4, 4-substituted by pyrrolidinyl |
NO20075650A NO20075650L (no) | 2005-05-19 | 2007-11-06 | Tri- eller tetrasubstituterte 3-aminopyrrolidinderivater |
HK08106844.7A HK1116774A1 (en) | 2005-05-19 | 2008-06-19 | Tri- or tetra-substituted-3-aminopyrrolidine derivatives |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005146386 | 2005-05-19 | ||
JP2005-146386 | 2005-05-19 | ||
JP2005344514 | 2005-11-29 | ||
JP2005-344514 | 2005-11-29 | ||
JP2006-080629 | 2006-03-23 | ||
JP2006080629 | 2006-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006123792A1 true WO2006123792A1 (ja) | 2006-11-23 |
Family
ID=37431361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/310069 WO2006123792A1 (ja) | 2005-05-19 | 2006-05-19 | トリ-、テトラ-置換-3-アミノピロリジン誘導体 |
Country Status (16)
Country | Link |
---|---|
US (3) | US7563805B2 (ja) |
EP (2) | EP2463274A1 (ja) |
JP (2) | JP5087394B2 (ja) |
KR (1) | KR101307717B1 (ja) |
AR (1) | AR054272A1 (ja) |
AU (1) | AU2006248354B2 (ja) |
BR (1) | BRPI0610114A2 (ja) |
CA (1) | CA2608468C (ja) |
ES (1) | ES2422858T3 (ja) |
HK (1) | HK1116774A1 (ja) |
IL (1) | IL186815A (ja) |
MY (1) | MY143605A (ja) |
NO (1) | NO20075650L (ja) |
NZ (1) | NZ562959A (ja) |
TW (1) | TWI384987B (ja) |
WO (1) | WO2006123792A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007037330A1 (ja) * | 2005-09-28 | 2007-04-05 | Daiichi Sankyo Company, Limited | キノロン含有凍結乾燥製剤の製造方法 |
WO2007111023A1 (ja) * | 2006-03-27 | 2007-10-04 | Daiichi Sankyo Company, Limited | 医薬用水和物 |
JP2008231067A (ja) * | 2007-03-23 | 2008-10-02 | Dai Ichi Seiyaku Co Ltd | キノロン含有凍結乾燥製剤の製造方法 |
JP2010515663A (ja) * | 2007-01-05 | 2010-05-13 | 第一三共株式会社 | フューズ置換型アミノピロリジン誘導体 |
US7842818B2 (en) | 2005-09-28 | 2010-11-30 | Daiichi Sankyo Company, Limited | Process for preparation of tetrasubstituted 5-azaspiro[2.4]- heptane derivatives and optically active intermediates thereof |
JP2010540440A (ja) * | 2007-09-21 | 2010-12-24 | エピファニー バイオサイエンシズ, インク. | バロマシクロビル多形体 |
US7977346B2 (en) | 2006-01-17 | 2011-07-12 | Guoqing Paul Chen | Spiro compounds and methods of use |
JP5017101B2 (ja) * | 2005-05-20 | 2012-09-05 | 第一三共株式会社 | 不斉四置換炭素原子含有化合物の製法 |
WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4820290B2 (ja) * | 2004-05-13 | 2011-11-24 | 第一三共株式会社 | 置換ピロリジン誘導体 |
TW200640899A (en) * | 2005-01-21 | 2006-12-01 | Daiichi Seiyaku Co | Fluoroalkylpyrrolidine derivative |
US7563805B2 (en) | 2005-05-19 | 2009-07-21 | Daiichi Pharmaceutical Co., Ltd. | Tri-, tetra-substituted-3-aminopyrrolidine derivative |
WO2010124005A1 (en) * | 2009-04-21 | 2010-10-28 | Purdue Research Foundation | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor |
JP5669984B2 (ja) | 2011-05-18 | 2015-02-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | 5−アザスピロ[2.4]ヘプタン−6−カルボン酸およびその誘導体の製造方法 |
EP2950428A4 (en) | 2013-01-25 | 2016-02-17 | Iai Corp | ACTUATOR |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5872589A (ja) * | 1981-10-28 | 1983-04-30 | Dai Ichi Seiyaku Co Ltd | ピリド〔1,2,3−de〕〔1,4〕ベンゾオキサジン誘導体 |
EP0172651A1 (en) * | 1984-07-20 | 1986-02-26 | Warner-Lambert Company | Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acids; substituted-5-amino-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds |
JPS61137885A (ja) * | 1984-12-08 | 1986-06-25 | Dainippon Pharmaceut Co Ltd | 1,8−ナフチリジン誘導体、そのエステルおよびその塩 |
EP0259804A2 (de) * | 1986-09-12 | 1988-03-16 | F. Hoffmann-La Roche Ag | Pyrido [3,2,1-ij]-1,3,4-benzoxadiazinderivate, Verfahren zu deren Herstellung, entsprechende pharmazeutische Präparate und im Verfahren verwendbare Zwischenprodukte |
US4735949A (en) * | 1986-02-18 | 1988-04-05 | Warner-Lambert Company | Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents |
EP0265230A1 (en) * | 1986-10-20 | 1988-04-27 | Warner-Lambert Company | Substituted-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids, derivatives thereof, pharmaceutical compositions comprising the compounds, and processes for producing the compounds |
EP0266576A2 (en) * | 1986-10-08 | 1988-05-11 | Bristol-Myers Squibb Company | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents |
JPS63130594A (ja) * | 1986-11-21 | 1988-06-02 | Tokyo Tanabe Co Ltd | ベンゾ〔ij〕キノリジン−2−カルボン酸化合物及びその製造法 |
JPS63152318A (ja) * | 1986-08-07 | 1988-06-24 | Dainippon Pharmaceut Co Ltd | 抗マイコプラズマ剤 |
JPS63188626A (ja) * | 1987-01-30 | 1988-08-04 | Dainippon Pharmaceut Co Ltd | ピリドンカルボン酸の可溶化方法 |
JPS643181A (en) * | 1987-06-23 | 1989-01-06 | Sankyo Co Ltd | Pyridonecarboxylic acid derivative |
EP0341493A2 (en) * | 1988-04-27 | 1989-11-15 | Daiichi Pharmaceutical Co., Ltd. | Optically active pyridonecarboxylic acid derivatives |
EP0470578A1 (en) * | 1990-08-09 | 1992-02-12 | Wakunaga Seiyaku Kabushiki Kaisha | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same |
JPH0474167A (ja) * | 1990-07-16 | 1992-03-09 | Dainippon Pharmaceut Co Ltd | 新規キノリンカルボン酸誘導体、そのエステルおよびその塩 |
EP0523512A1 (de) * | 1991-07-19 | 1993-01-20 | Bayer Ag | 8-Vinyl- und 8-Ethinyl-chinoloncarbonsäuren |
JPH05279364A (ja) * | 1992-02-07 | 1993-10-26 | Wakunaga Pharmaceut Co Ltd | 新規三環性化合物又はその塩及びこれを含有する抗菌剤 |
EP0593766A1 (en) * | 1991-05-28 | 1994-04-27 | Daiichi Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivative |
EP0596126A1 (en) * | 1991-12-27 | 1994-05-11 | Wakunaga Seiyaku Kabushiki Kaisha | Novel quinolone derivative or salt thereof and antibacterial containing the same |
JPH06228138A (ja) * | 1993-02-03 | 1994-08-16 | Fujisawa Pharmaceut Co Ltd | ピリドシンノリン化合物またはその塩及びこれを含有する抗菌剤 |
JPH0725873A (ja) * | 1993-07-09 | 1995-01-27 | Wakunaga Pharmaceut Co Ltd | キノロン誘導体又はその塩並びに該化合物を含有する抗菌剤 |
EP0700912A1 (en) * | 1993-05-24 | 1996-03-13 | Wakunaga Seiyaku Kabushiki Kaisha | Quinolone derivative or salt thereof, and antibacterial containing the same |
WO1996023775A1 (fr) * | 1995-01-30 | 1996-08-08 | Wakunaga Seiyaku Kabushiki Kaisha | Nouveaux derives d'acide pyridonecarboxylique ou de ses sels et agent antibacterien contenant ces derives en tant qu'ingredient actif |
EP0787726A1 (en) * | 1994-06-14 | 1997-08-06 | Dainippon Pharmaceutical Co., Ltd. | Novel compound, process for producing the same, and antitumor agent |
EP0787720A1 (en) * | 1994-10-20 | 1997-08-06 | Wakunaga Seiyaku Kabushiki Kaisha | Novel pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient |
JPH09221424A (ja) * | 1995-12-13 | 1997-08-26 | Dainippon Pharmaceut Co Ltd | 抗腫瘍剤 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61152682A (ja) | 1984-12-27 | 1986-07-11 | Dainippon Pharmaceut Co Ltd | ピリドンカルボン酸誘導体、そのエステルおよびその塩 |
JPS61282382A (ja) | 1985-06-06 | 1986-12-12 | Dainippon Pharmaceut Co Ltd | フエニル置換1,8−ナフチリジン誘導体、そのエステルおよびその塩 |
JPH0635457B2 (ja) * | 1985-06-28 | 1994-05-11 | 杏林製薬株式会社 | ピリドンカルボン酸誘導体およびその製造方法 |
JPS63198664A (ja) * | 1986-03-31 | 1988-08-17 | Sankyo Co Ltd | キノロンカルボン酸誘導体 |
EP0242789A3 (en) * | 1986-04-25 | 1990-09-05 | Dainippon Pharmaceutical Co., Ltd. | Novel quinoline derivates and processes for preparation thereof |
ZW16387A1 (en) * | 1986-09-12 | 1988-05-25 | Hoffmann La Roche | Tricyclic compounds |
WO1991001308A1 (fr) * | 1989-07-21 | 1991-02-07 | Ss Pharmaceutical Co., Ltd. | Derives de l'acide quinolonecarboxylique |
US5286723A (en) | 1988-08-31 | 1994-02-15 | Daiichi Seiyaku Co., Ltd. | Spiro compound |
CA1336090C (en) | 1988-08-31 | 1995-06-27 | Isao Hayakawa | Spiro-substituted cyclic amines of quinolone derivatives |
JP2807277B2 (ja) | 1988-08-31 | 1998-10-08 | 第一製薬株式会社 | スピロ化合物 |
JPH0559052A (ja) * | 1990-08-09 | 1993-03-09 | Wakunaga Pharmaceut Co Ltd | 新規三環性化合物又はその塩及びこれを含有する抗菌剤 |
US5468742A (en) | 1991-07-19 | 1995-11-21 | Bayer Aktiengesellschaft | 8-vinyl- and 9-ethinyl-quinolone-carboxylic acids |
WO1993025545A1 (en) * | 1992-06-09 | 1993-12-23 | Korea Research Institute Of Chemical Technology | Novel quinoline derivatives and processes for preparing the same |
AU8038798A (en) | 1997-06-24 | 1999-01-04 | Daiichi Pharmaceutical Co., Ltd. | Cis-substituted fluoromethylpyrrolidine derivatives |
AR027761A1 (es) | 2000-03-31 | 2003-04-09 | Daiichi Seiyaku Co | Un derivado del acido quinolonacarboxilico, las composiciones antibacterianas que lo contienen y el uso de dicho derivado para la elaboracion de drogaspara el tratamiento de enfermedades infecciosas |
EP1712554A1 (en) * | 2004-02-02 | 2006-10-18 | Daiichi Pharmaceutical Co., Ltd. | Pyridobenzoxazine derivative |
JP4820290B2 (ja) | 2004-05-13 | 2011-11-24 | 第一三共株式会社 | 置換ピロリジン誘導体 |
US7563805B2 (en) | 2005-05-19 | 2009-07-21 | Daiichi Pharmaceutical Co., Ltd. | Tri-, tetra-substituted-3-aminopyrrolidine derivative |
-
2006
- 2006-04-28 US US11/413,153 patent/US7563805B2/en not_active Expired - Fee Related
- 2006-05-05 MY MYPI20062086A patent/MY143605A/en unknown
- 2006-05-17 TW TW095117509A patent/TWI384987B/zh not_active IP Right Cessation
- 2006-05-18 AR AR20060102021A patent/AR054272A1/es unknown
- 2006-05-19 CA CA2608468A patent/CA2608468C/en not_active Expired - Fee Related
- 2006-05-19 BR BRPI0610114-3A patent/BRPI0610114A2/pt not_active IP Right Cessation
- 2006-05-19 NZ NZ562959A patent/NZ562959A/en not_active IP Right Cessation
- 2006-05-19 ES ES06746676T patent/ES2422858T3/es active Active
- 2006-05-19 AU AU2006248354A patent/AU2006248354B2/en not_active Ceased
- 2006-05-19 KR KR1020077026606A patent/KR101307717B1/ko not_active IP Right Cessation
- 2006-05-19 EP EP12001575A patent/EP2463274A1/en not_active Withdrawn
- 2006-05-19 EP EP06746676.3A patent/EP1882689B1/en active Active
- 2006-05-19 WO PCT/JP2006/310069 patent/WO2006123792A1/ja active Application Filing
- 2006-05-19 JP JP2007516357A patent/JP5087394B2/ja not_active Expired - Fee Related
-
2007
- 2007-10-21 IL IL186815A patent/IL186815A/en not_active IP Right Cessation
- 2007-11-06 NO NO20075650A patent/NO20075650L/no not_active Application Discontinuation
-
2008
- 2008-06-19 HK HK08106844.7A patent/HK1116774A1/xx not_active IP Right Cessation
-
2009
- 2009-04-13 US US12/422,726 patent/US8211910B2/en not_active Expired - Fee Related
-
2012
- 2012-04-25 US US13/455,486 patent/US8476429B2/en not_active Expired - Fee Related
- 2012-07-09 JP JP2012153741A patent/JP5475841B2/ja not_active Expired - Fee Related
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5872589A (ja) * | 1981-10-28 | 1983-04-30 | Dai Ichi Seiyaku Co Ltd | ピリド〔1,2,3−de〕〔1,4〕ベンゾオキサジン誘導体 |
EP0172651A1 (en) * | 1984-07-20 | 1986-02-26 | Warner-Lambert Company | Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acids; substituted-5-amino-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds |
JPS61137885A (ja) * | 1984-12-08 | 1986-06-25 | Dainippon Pharmaceut Co Ltd | 1,8−ナフチリジン誘導体、そのエステルおよびその塩 |
US4735949A (en) * | 1986-02-18 | 1988-04-05 | Warner-Lambert Company | Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents |
JPS63152318A (ja) * | 1986-08-07 | 1988-06-24 | Dainippon Pharmaceut Co Ltd | 抗マイコプラズマ剤 |
EP0259804A2 (de) * | 1986-09-12 | 1988-03-16 | F. Hoffmann-La Roche Ag | Pyrido [3,2,1-ij]-1,3,4-benzoxadiazinderivate, Verfahren zu deren Herstellung, entsprechende pharmazeutische Präparate und im Verfahren verwendbare Zwischenprodukte |
EP0266576A2 (en) * | 1986-10-08 | 1988-05-11 | Bristol-Myers Squibb Company | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents |
EP0265230A1 (en) * | 1986-10-20 | 1988-04-27 | Warner-Lambert Company | Substituted-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids, derivatives thereof, pharmaceutical compositions comprising the compounds, and processes for producing the compounds |
JPS63130594A (ja) * | 1986-11-21 | 1988-06-02 | Tokyo Tanabe Co Ltd | ベンゾ〔ij〕キノリジン−2−カルボン酸化合物及びその製造法 |
JPS63188626A (ja) * | 1987-01-30 | 1988-08-04 | Dainippon Pharmaceut Co Ltd | ピリドンカルボン酸の可溶化方法 |
JPS643181A (en) * | 1987-06-23 | 1989-01-06 | Sankyo Co Ltd | Pyridonecarboxylic acid derivative |
EP0341493A2 (en) * | 1988-04-27 | 1989-11-15 | Daiichi Pharmaceutical Co., Ltd. | Optically active pyridonecarboxylic acid derivatives |
JPH0474167A (ja) * | 1990-07-16 | 1992-03-09 | Dainippon Pharmaceut Co Ltd | 新規キノリンカルボン酸誘導体、そのエステルおよびその塩 |
EP0470578A1 (en) * | 1990-08-09 | 1992-02-12 | Wakunaga Seiyaku Kabushiki Kaisha | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same |
EP0593766A1 (en) * | 1991-05-28 | 1994-04-27 | Daiichi Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivative |
EP0523512A1 (de) * | 1991-07-19 | 1993-01-20 | Bayer Ag | 8-Vinyl- und 8-Ethinyl-chinoloncarbonsäuren |
EP0596126A1 (en) * | 1991-12-27 | 1994-05-11 | Wakunaga Seiyaku Kabushiki Kaisha | Novel quinolone derivative or salt thereof and antibacterial containing the same |
JPH05279364A (ja) * | 1992-02-07 | 1993-10-26 | Wakunaga Pharmaceut Co Ltd | 新規三環性化合物又はその塩及びこれを含有する抗菌剤 |
JPH06228138A (ja) * | 1993-02-03 | 1994-08-16 | Fujisawa Pharmaceut Co Ltd | ピリドシンノリン化合物またはその塩及びこれを含有する抗菌剤 |
EP0700912A1 (en) * | 1993-05-24 | 1996-03-13 | Wakunaga Seiyaku Kabushiki Kaisha | Quinolone derivative or salt thereof, and antibacterial containing the same |
JPH0725873A (ja) * | 1993-07-09 | 1995-01-27 | Wakunaga Pharmaceut Co Ltd | キノロン誘導体又はその塩並びに該化合物を含有する抗菌剤 |
EP0787726A1 (en) * | 1994-06-14 | 1997-08-06 | Dainippon Pharmaceutical Co., Ltd. | Novel compound, process for producing the same, and antitumor agent |
EP0787720A1 (en) * | 1994-10-20 | 1997-08-06 | Wakunaga Seiyaku Kabushiki Kaisha | Novel pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient |
WO1996023775A1 (fr) * | 1995-01-30 | 1996-08-08 | Wakunaga Seiyaku Kabushiki Kaisha | Nouveaux derives d'acide pyridonecarboxylique ou de ses sels et agent antibacterien contenant ces derives en tant qu'ingredient actif |
JPH09221424A (ja) * | 1995-12-13 | 1997-08-26 | Dainippon Pharmaceut Co Ltd | 抗腫瘍剤 |
Non-Patent Citations (2)
Title |
---|
FRANZBLAU S.G. ET AL.: "Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 34, no. 2, 1990, pages 229 - 231, XP002941443 * |
See also references of EP1882689A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5017101B2 (ja) * | 2005-05-20 | 2012-09-05 | 第一三共株式会社 | 不斉四置換炭素原子含有化合物の製法 |
WO2007037330A1 (ja) * | 2005-09-28 | 2007-04-05 | Daiichi Sankyo Company, Limited | キノロン含有凍結乾燥製剤の製造方法 |
US7842818B2 (en) | 2005-09-28 | 2010-11-30 | Daiichi Sankyo Company, Limited | Process for preparation of tetrasubstituted 5-azaspiro[2.4]- heptane derivatives and optically active intermediates thereof |
US8129533B2 (en) | 2005-09-28 | 2012-03-06 | Dalichi Sankyo Company, Limited | Method for production of quinolone-containing lyophilized preparation |
US7977346B2 (en) | 2006-01-17 | 2011-07-12 | Guoqing Paul Chen | Spiro compounds and methods of use |
WO2007111023A1 (ja) * | 2006-03-27 | 2007-10-04 | Daiichi Sankyo Company, Limited | 医薬用水和物 |
US8003666B2 (en) | 2006-03-27 | 2011-08-23 | Daiichi Sankyo Company, Limited | Hydrate for medical purposes |
JP2010515663A (ja) * | 2007-01-05 | 2010-05-13 | 第一三共株式会社 | フューズ置換型アミノピロリジン誘導体 |
JP2008231067A (ja) * | 2007-03-23 | 2008-10-02 | Dai Ichi Seiyaku Co Ltd | キノロン含有凍結乾燥製剤の製造方法 |
JP2010540440A (ja) * | 2007-09-21 | 2010-12-24 | エピファニー バイオサイエンシズ, インク. | バロマシクロビル多形体 |
WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
Also Published As
Publication number | Publication date |
---|---|
BRPI0610114A2 (pt) | 2010-06-01 |
EP1882689A4 (en) | 2010-01-06 |
JPWO2006123792A1 (ja) | 2008-12-25 |
NO20075650L (no) | 2007-12-13 |
US7563805B2 (en) | 2009-07-21 |
TW200716131A (en) | 2007-05-01 |
JP5087394B2 (ja) | 2012-12-05 |
KR101307717B1 (ko) | 2013-09-11 |
US20120232288A1 (en) | 2012-09-13 |
KR20080020603A (ko) | 2008-03-05 |
US8476429B2 (en) | 2013-07-02 |
CA2608468C (en) | 2013-02-26 |
CA2608468A1 (en) | 2006-11-23 |
HK1116774A1 (en) | 2009-01-02 |
AR054272A1 (es) | 2007-06-13 |
EP1882689B1 (en) | 2013-07-10 |
AU2006248354B2 (en) | 2011-11-03 |
TWI384987B (zh) | 2013-02-11 |
US8211910B2 (en) | 2012-07-03 |
JP5475841B2 (ja) | 2014-04-16 |
US20060264428A1 (en) | 2006-11-23 |
EP2463274A1 (en) | 2012-06-13 |
AU2006248354A1 (en) | 2006-11-23 |
EP1882689A1 (en) | 2008-01-30 |
US20090253726A1 (en) | 2009-10-08 |
ES2422858T3 (es) | 2013-09-16 |
IL186815A (en) | 2013-09-30 |
JP2012193195A (ja) | 2012-10-11 |
MY143605A (en) | 2011-06-15 |
IL186815A0 (en) | 2008-02-09 |
NZ562959A (en) | 2010-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006123792A1 (ja) | トリ-、テトラ-置換-3-アミノピロリジン誘導体 | |
CA2574307A1 (en) | Rifamycin derivatives for treating microbial infections | |
TW200946528A (en) | Piperidine derivatives | |
CN110869373B (zh) | 抗生素抗性破坏剂 | |
JP2015500824A (ja) | 新規ピロール誘導体 | |
EP3490984A1 (en) | 2-pyrrolidine phenylhydrazides antibacterial agents | |
RU2248970C2 (ru) | Циклоалкилзамещенные производные аминометилпирролидина и антибактериальный агент на их основе | |
TW200944532A (en) | Novel 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | |
WO2005111015A1 (ja) | 置換ピロリジン誘導体 | |
JPH10287669A (ja) | 置換アミノメチルピロリジン誘導体 | |
AU726378B2 (en) | Cycloalkylaminomethylpyrrolidine derivatives | |
WO2005073238A1 (ja) | ピリドベンズオキサジン誘導体 | |
CN101189222B (zh) | 三-、四-取代-3-氨基吡咯烷衍生物 | |
JP5063032B2 (ja) | トリ−、テトラ−置換−3−アミノピロリジン誘導体 | |
JP4926723B2 (ja) | フルオロアルキルピロリジン誘導体 | |
RU2420524C2 (ru) | Производные три- или тетра-замещенного-3-аминопирролидина | |
CN113087724A (zh) | 异噻唑并嘧啶酮类化合物,包含其的药物组合物及其用途 | |
JP4619952B2 (ja) | 8−シアノキノロンカルボン酸誘導体 | |
MX2007014535A (es) | Derivado de 3-aminopirrolidina trisustituido o tetrasustituido. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680017206.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007516357 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006746676 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 186815 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8200/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006248354 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 562959 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007502433 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2608468 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077026606 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/014535 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07121967 Country of ref document: CO |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200702470 Country of ref document: VN |
|
ENP | Entry into the national phase |
Ref document number: 2006248354 Country of ref document: AU Date of ref document: 20060519 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006248354 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007147217 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006746676 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0610114 Country of ref document: BR Kind code of ref document: A2 |